In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice
about
Targeting the latent reservoir to achieve functional HIV cureNK Cells in HIV DiseaseInsufficient natural killer cell responses against retroviruses: how to improve NK cell killing of retrovirus-infected cellsA Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV InfectionHIV-specific CD8⁺ T cells and HIV eradicationIn vivo platforms for analysis of HIV persistence and eradication.Roles of natural killer cells in antiviral immunityIL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas.Evaluation of Functional NK Cell Responses in Vaccinated and SIV-Infected Rhesus MacaquesRole of Natural Killer Cells in HIV-Associated Malignancies.IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis.A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses.Dose of Retroviral Infection Determines Induction of Antiviral NK Cell Responses.HIV-I Nef inhibitors: a novel class of HIV-specific immune adjuvants in support of a cure.Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent.Potent In Vivo NK Cell-mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-bispecific and Hexavalent Broadly Neutralizing Fusion Protein.Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2 Inhibition.A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.Trans-presentation of interleukin-15 by interleukin-15 receptor alpha is dispensable for the pathogenesis of autoimmune type 1 diabetes.New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity.Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse.Type I Interferon Responses by HIV-1 Infection: Association with Disease Progression and Control.Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control.Can NK cells purge HIV sanctuaries?Regulatory T cells (Tregs): A major immune checkpoint to consider in combinatorial therapeutic HIV-1 vaccines.Exposure to Prostratin but Not Bryostatin-1 Improves Natural Killer Cell Functions Including Killing of CD4 T Cells Harboring Reactivated Human Immunodeficiency Virus
P2860
Q26745923-1E1FC935-E362-405C-83C6-5281641F59F7Q26752833-C07132EB-DC91-49FB-A0BE-41C29952239EQ28068375-91437B48-44C4-429C-A13B-79ED5F3185AFQ30385378-4382D3FE-26B9-49AD-88F0-5445B19091A4Q33620546-1C07C4D8-C829-4CB8-8FC5-938E45B2FA78Q36515071-3DD129C9-8F15-48DF-BDE8-7A133AA276EDQ36515119-F5CD2A9D-4609-4225-8D47-8D7F38209CB0Q36767761-09A167FA-6594-430F-BF9C-72F932492BDFQ37085973-3E1587CA-8FD8-4669-91BB-B35D9F2A246BQ37218449-2BC40D60-2DFE-4BBC-AFF7-1FC2FEC438DCQ37712593-E7D8A45D-B950-461B-961E-177372F9009DQ38720858-92EFB9C9-0C52-4474-AEA0-9C7696CA1260Q38744668-043AA3FD-C09D-4D02-B7C2-0809B18F8B43Q40042449-975AFBDD-4F7A-4FD8-A764-88DEFA89578DQ40047184-8383D5FD-2E91-4990-A227-25322E2F86DEQ40049630-3BC5AABA-7D5A-4AEE-B565-41720CAEFBD6Q40088787-813BB5C8-3B4A-4945-B412-5E7495E1DF04Q40279377-E8E46BBA-CEF3-4814-9433-3F2CE76A81B0Q40336664-2C06FC13-93AA-402E-B913-0AE3FC685348Q40924333-CFC93682-86D3-459E-A8FB-F6B6B47104D6Q41279994-B4DD7496-6707-4013-9E43-D12BE9F16CABQ47156423-F44497AE-B249-49D3-8A7C-6670865DC743Q47548056-1B406115-8C97-4D7F-AC8F-7ED0D71D5905Q47568646-2C1AA085-CC40-4A7E-9E82-E530031AC1F8Q47586524-7B8BEE00-4146-4B15-A448-98F1C0C81857Q50424105-419BD4E6-E365-488B-B645-E0E665450F13Q57565007-DB7A93C8-C53A-45A1-85E3-F882E36A5105
P2860
In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
In Vivo Activation of Human NK ...... -1 Infection in Humanized Mice
@ast
In Vivo Activation of Human NK ...... -1 Infection in Humanized Mice
@en
type
label
In Vivo Activation of Human NK ...... -1 Infection in Humanized Mice
@ast
In Vivo Activation of Human NK ...... -1 Infection in Humanized Mice
@en
prefLabel
In Vivo Activation of Human NK ...... -1 Infection in Humanized Mice
@ast
In Vivo Activation of Human NK ...... -1 Infection in Humanized Mice
@en
P2093
P2860
P356
P1433
P1476
In Vivo Activation of Human NK ...... -1 Infection in Humanized Mice
@en
P2093
Candice Church
Christina Ochsenbauer
Emily K Jeng
Harris Goldstein
Hing C Wong
Jian Hua Zheng
John C Kappes
Kathryn Deneroff
Kieran Seay
P2860
P304
P356
10.1128/JVI.00563-15
P407
P577
2015-04-01T00:00:00Z